Multiple Myeloma Foundation

Multiple Myeloma (MM) is a clonal plasma cell malignancy. The CRAB criteria remain the definitive clinical guidelines for identifying symptomatic disease requiring systemic therapy.

C

Calcium

Hypercalcemia from bone lysis.

R

Renal

Insufficiency from M-protein burden.

A

Anemia

Low Hgb due to marrow crowding.

B

Bone

Lytic lesions and skeletal fractures.

Firstline Treatment & Mechanisms

Induction therapy for newly diagnosed patients utilizes distinct biological pathways. Below is the critical difference between the intracellular proteasome targeting and extracellular CD38 targeting.

INTERNAL TARGETING (INTRACELLULAR)
PI (Proteasome Inhibitor)

Bortezomib

Mechanism: Inhibits the 26S proteasome trash-disposal system. High antibody production in plasma cells leads to toxic protein buildup, triggering apoptosis from within.

EXTERNAL TARGETING (SURFACE BEACON)
mAb (Monoclonal Antibody)

Daratumumab

Mechanism: Binds surface CD38. Acts as an immune beacon, recruiting NK cells and Macrophages to lyse the myeloma cell via ADCC.

IMiD

Lenalidomide

Targets Cereblon (CRBN) to degrade survival transcription factors. Foundation of maintenance care.

Steroid

Dexamethasone

Potentiates cell death across classes by suppressing inflammatory marrow signaling.

Defining RRMM

Relapsed/Refractory (RRMM) describes disease return or progression while on treatment. DREAMM-7 addresses patients reaching 1st relapse who are often refractory to frontline Lenalidomide and CD38 targeting.

RRMM Therapeutic Journey

Standard of care evolution from non-specific alkylators to high-potency targeted ADCs.

1960s - 1990s

Cytotoxic Era

MP was the primary option. Median survival was limited to ~3 years.

2000 - 2015

The Triplet Shift

PIs (Bortezomib) and IMiDs transformed relapsed outcomes.

2016 - 2023

CD38 Dominance

DVd (CASTOR) and DRd (POLLUX) established the global 2nd-line standard.

Current Era

DREAMM-7 Landmark

BVd tripling PFS vs Daratumumab standard in early relapse.

Spotlight: Belantamab Mafodotin (ADC)

First-in-class Antibody-Drug Conjugate (ADC) targeting BCMA.

1

Targeting: Antibody binds specifically to BCMA on the cell surface.

2

Cytotoxicity: Internalized ADC releases mafodotin to disrupt microtubules.

Role in DREAMM-7

By targeting BCMA instead of CD38, it bypasses the immune escape seen in patients failing 1L CD38-monoclonal antibodies.

Trial Evidence Dashboard

Clinical Endpoint Definitions

PFS
Progression-Free Survival

Definition: Time from starting treatment until disease progresses or patient dies.

📌 How long can we keep the cancer from getting worse?

ORR
Overall Response Rate

Definition: % of patients who achieve ≥ Partial Response (PR).

Includes:

  • Partial Response (PR)
  • Complete Response (CR)

📌 How many patients actually respond to the drug?

CR
Complete Response

Definition: No detectable disease using standard clinical tests.

In multiple myeloma:

  • No M-protein in blood/urine
  • Normal bone marrow (no clonal plasma cells)

📌 We can't see the cancer anymore with routine testing

MRD-
Minimal Residual Disease Negative

Definition: No detectable cancer cells using very sensitive testing (flow cytometry or sequencing).

Sensitivity: Detects down to 1 cancer cell in 100,000 cells (10⁻⁵).

📌 Even microscopic disease is gone

Median PFS (Months)

BVd (36.6m) vs DVd (13.4m). HR 0.41. Nearly 2 years of additional remission.

Response Depth (%)

BVd doubled Complete Response (CR) and MRD-negativity rates vs standard.

The Clinical Verdict

Redefining the ceiling for RRMM care via early BCMA targeting.

Regimen Scorecard

Targeted Durability

Nearly triples median PFS vs Daratumumab standard.

Response Quality

Highest MRD-negativity rate ever reported in the 2nd line triplet setting.

Community Ready

Off-the-shelf ADC brings BCMA potency to community clinics.

The New Benchmark in Early Relapse RRMM.

Effective management of ocular toxicity unlocks unprecedented disease control.

📚 Sources & Clinical References

DREAMM-7 Trial Data

Hungria V, et al. (2024): Belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory MM. NEJM.
GSK DREAMM-7 press release: Grade 3/4 ocular AEs in 34% of BVd patients with 98% resolution and median time to resolution of 22 days. GSK press release.
CASTOR Trial (DVd standard): Palumbo A, et al. "Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma." NEJM 2016. NEJM.
POLLUX Trial (DRd standard): Dimopoulos MA, et al. "Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma." NEJM 2016. NEJM.

Mechanism & Guidelines

IMWG Diagnostic Criteria: Rajkumar SV, et al. "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma." The Lancet Oncology 2014. Lancet Oncology.
FDA Blenrep Prescribing Information: ADC mechanism, BCMA targeting, ocular toxicity management, and dosing. FDA label.
Velcade & Darzalex mechanism: FDA prescribing information for Bortezomib and Daratumumab supports intracellular proteasome inhibition vs surface CD38 targeting.
NCCN Multiple Myeloma Guidelines: Frontline and early relapse standards, including VRd, Dara-VRd, and ASCT eligibility. NCCN.